Zhejiang DiAn Diagnostics Co
Dian Diagnostics Group Co.,Ltd. provides integrated medical diagnostics solutions with independent diagnostic services in China. The company offers laboratory supplies and kits; AI-assisted digital pathology diagnosis solutions, such as nucleic acid extraction and purification system, automatic liquid-based cytology slide preparation and staining system, digital pathology slide scanner, automated… Read more
Zhejiang DiAn Diagnostics Co (300244) - Net Assets
Latest net assets as of September 2025: CN¥8.67 Billion CNY
Based on the latest financial reports, Zhejiang DiAn Diagnostics Co (300244) has net assets worth CN¥8.67 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥14.77 Billion) and total liabilities (CN¥6.09 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥8.67 Billion |
| % of Total Assets | 58.75% |
| Annual Growth Rate | 43.26% |
| 5-Year Change | 45.42% |
| 10-Year Change | 728.03% |
| Growth Volatility | 80.97 |
Zhejiang DiAn Diagnostics Co - Net Assets Trend (2008–2024)
This chart illustrates how Zhejiang DiAn Diagnostics Co's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Zhejiang DiAn Diagnostics Co (2008–2024)
The table below shows the annual net assets of Zhejiang DiAn Diagnostics Co from 2008 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥8.77 Billion | -11.49% |
| 2023-12-31 | CN¥9.90 Billion | +4.24% |
| 2022-12-31 | CN¥9.50 Billion | +27.10% |
| 2021-12-31 | CN¥7.48 Billion | +24.00% |
| 2020-12-31 | CN¥6.03 Billion | +17.33% |
| 2019-12-31 | CN¥5.14 Billion | +9.26% |
| 2018-12-31 | CN¥4.70 Billion | +59.59% |
| 2017-12-31 | CN¥2.95 Billion | +15.75% |
| 2016-12-31 | CN¥2.55 Billion | +140.45% |
| 2015-12-31 | CN¥1.06 Billion | +50.86% |
| 2014-12-31 | CN¥701.84 Million | +18.99% |
| 2013-12-31 | CN¥589.81 Million | +11.85% |
| 2012-12-31 | CN¥527.32 Million | +10.54% |
| 2011-12-31 | CN¥477.04 Million | +198.30% |
| 2010-12-31 | CN¥159.92 Million | +44.96% |
| 2009-12-31 | CN¥110.32 Million | +296.04% |
| 2008-12-31 | CN¥27.86 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Zhejiang DiAn Diagnostics Co's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 44004.4% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥4.03 Billion | 61.39% |
| Common Stock | CN¥624.98 Million | 9.52% |
| Other Comprehensive Income | CN¥386.14 Million | 5.88% |
| Other Components | CN¥1.52 Billion | 23.21% |
| Total Equity | CN¥6.56 Billion | 100.00% |
Zhejiang DiAn Diagnostics Co Competitors by Market Cap
The table below lists competitors of Zhejiang DiAn Diagnostics Co ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
All Ring Tech Co Ltd
TWO:6187
|
$1.14 Billion |
|
ACC Limited
NSE:ACC
|
$1.14 Billion |
|
Shenzhen Energy Group Co Ltd
SHE:000027
|
$1.14 Billion |
|
Wuhan Raycus Fiber Laser Technologies Co Ltd Class A
SHE:300747
|
$1.14 Billion |
|
WATCH.O.SWITZ.GR.LS-0125
F:5WS
|
$1.14 Billion |
|
Indraprastha Gas Limited
NSE:IGL
|
$1.14 Billion |
|
Dole PLC
NYSE:DOLE
|
$1.14 Billion |
|
Hunan Corun New Energy Co Ltd
SHG:600478
|
$1.14 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Zhejiang DiAn Diagnostics Co's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 7,566,265,438 to 6,564,302,204, a change of -1,001,963,234 (-13.2%).
- Net loss of 357,277,645 reduced equity.
- Dividend payments of 575,711,566 reduced retained earnings.
- Share repurchases of 199,573,525 reduced equity.
- Other comprehensive income increased equity by 386,143,472.
- Other factors decreased equity by 255,543,970.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-357.28 Million | -5.44% |
| Dividends Paid | CN¥575.71 Million | -8.77% |
| Share Repurchases | CN¥199.57 Million | -3.04% |
| Other Comprehensive Income | CN¥386.14 Million | +5.88% |
| Other Changes | CN¥-255.54 Million | -3.89% |
| Total Change | CN¥- | -13.24% |
Book Value vs Market Value Analysis
This analysis compares Zhejiang DiAn Diagnostics Co's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.83x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 190.64x to 1.83x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-12-31 | CN¥0.10 | CN¥19.61 | x |
| 2009-12-31 | CN¥0.40 | CN¥19.61 | x |
| 2010-12-31 | CN¥0.45 | CN¥19.61 | x |
| 2011-12-31 | CN¥1.15 | CN¥19.61 | x |
| 2012-12-31 | CN¥1.06 | CN¥19.61 | x |
| 2013-12-31 | CN¥1.20 | CN¥19.61 | x |
| 2014-12-31 | CN¥1.40 | CN¥19.61 | x |
| 2015-12-31 | CN¥1.91 | CN¥19.61 | x |
| 2016-12-31 | CN¥3.81 | CN¥19.61 | x |
| 2017-12-31 | CN¥4.31 | CN¥19.61 | x |
| 2018-12-31 | CN¥6.72 | CN¥19.61 | x |
| 2019-12-31 | CN¥6.42 | CN¥19.61 | x |
| 2020-12-31 | CN¥7.57 | CN¥19.61 | x |
| 2021-12-31 | CN¥9.42 | CN¥19.61 | x |
| 2022-12-31 | CN¥11.94 | CN¥19.61 | x |
| 2023-12-31 | CN¥12.10 | CN¥19.61 | x |
| 2024-12-31 | CN¥10.72 | CN¥19.61 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Zhejiang DiAn Diagnostics Co utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -5.44%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -2.93%
- • Asset Turnover: 0.77x
- • Equity Multiplier: 2.40x
- Recent ROE (-5.44%) is below the historical average (14.08%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | 27.15% | 3.70% | 1.61x | 4.57x | CN¥4.16 Million |
| 2009 | 16.29% | 6.52% | 1.47x | 1.70x | CN¥6.63 Million |
| 2010 | 21.37% | 9.44% | 1.47x | 1.54x | CN¥17.24 Million |
| 2011 | 9.09% | 8.75% | 0.80x | 1.29x | CN¥-4.22 Million |
| 2012 | 11.82% | 8.52% | 1.00x | 1.39x | CN¥9.28 Million |
| 2013 | 14.93% | 8.48% | 1.25x | 1.41x | CN¥28.43 Million |
| 2014 | 18.22% | 9.33% | 1.20x | 1.62x | CN¥56.20 Million |
| 2015 | 18.86% | 9.41% | 0.81x | 2.47x | CN¥82.11 Million |
| 2016 | 12.59% | 6.87% | 0.67x | 2.74x | CN¥53.99 Million |
| 2017 | 14.86% | 6.99% | 0.68x | 3.14x | CN¥114.40 Million |
| 2018 | 10.57% | 5.58% | 0.65x | 2.90x | CN¥21.01 Million |
| 2019 | 8.72% | 4.11% | 0.79x | 2.70x | CN¥-51.10 Million |
| 2020 | 17.09% | 7.54% | 0.86x | 2.64x | CN¥333.15 Million |
| 2021 | 19.91% | 8.89% | 0.84x | 2.67x | CN¥578.69 Million |
| 2022 | 19.26% | 7.07% | 0.96x | 2.83x | CN¥689.38 Million |
| 2023 | 4.06% | 2.29% | 0.75x | 2.37x | CN¥-449.17 Million |
| 2024 | -5.44% | -2.93% | 0.77x | 2.40x | CN¥-1.01 Billion |
Industry Comparison
This section compares Zhejiang DiAn Diagnostics Co's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $2,018,763,768
- Average return on equity (ROE) among peers: 5.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Zhejiang DiAn Diagnostics Co (300244) | CN¥8.67 Billion | 27.15% | 0.70x | $1.14 Billion |
| Berry Genomics Co Ltd (000710) | $108.87 Million | -46.67% | 1.22x | $377.87 Million |
| Beijing Strong Biotechnologies Inc (300406) | $1.70 Billion | 17.66% | 0.10x | $317.93 Million |
| Ningbo MedicalSystem Biotechnology Co Ltd (300439) | $308.32 Million | 33.58% | 0.53x | $283.14 Million |
| Maccura Biotechnology Co Ltd (300463) | $4.54 Billion | 21.06% | 0.45x | $576.46 Million |
| Guangdong Hybribio Biotech Co Ltd (300639) | $4.05 Billion | -16.18% | 0.14x | $319.65 Million |
| BGI Genomics Co Ltd (300676) | $4.25 Billion | 9.09% | 0.23x | $1.45 Billion |
| Amoy Diagnostics Co Ltd (300685) | $307.91 Million | 21.77% | 0.15x | $834.75 Million |
| Shanghai Labway Clinical Laboratory Co Ltd (301060) | $1.82 Billion | -6.01% | 0.44x | $226.85 Million |
| SMO ClinPlus Co. Ltd. (301257) | $1.08 Billion | 12.47% | 0.26x | $347.98 Million |